Cardiovascular
Bedtime versus morning antihypertensive dosing can change event rates — timing is a modifiable lever in BP pathways.
Strong clinical proof
Evidence converges.
Dose timing shapes cardiovascular, metabolic, and safety outcomes; evidence now supports clinical deployment.
Metabolic
Circadian disruption from light–dark misalignment links to insulin resistance and type 2 diabetes risk.
Safety
Clearer timing guidance supports medication safety, adherence, and fewer avoidable treatment escalations.